Pharmion Corporation Announces FDA Approval Of Vidaza NDA Supplement For IV Administration

... Pharmion Corporation (Nasdaq: PHRM) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) supplement to add intravenous (IV) use as a new route of administration to the instructions in the approved prescribing information for its DNA demethylating agent Vidaza(R) (azacitidine for injection). [click link for full article] ...